Adaptimmune opens U.S. headquarters at the Navy Yard to develop cancer therapies
Adaptimmune Therapeutics, a biopharmaceutical company developing T-cell therapies to treat cancer, opened its new U.S. headquarters Wednesday at the Navy Yard in South Philadelphia.
The 47,400-square foot building will accommodate clinical drug development and a manufacturing plant. The Oxford, U.K.-based company employs 92 in Philadelphia, and will grow to 120 by the end of 2017. Adaptimmune has 201 employees in the U.K.
Established in 2008, Adaptimmune aims to utilize the body's ow...